MiR-99a-5p Inhibits Glycolysis and Induces Cell Apoptosis in Cervical Cancer by Targeting RRAGD
Overview
Authors
Affiliations
Cervical cancer (CC) is one of the most common gynecological malignancies that endangers women's health. A negative effect of glycolysis is that it contributes to abnormal tumor growth. MicroRNA (miR)-99a expression has been found to be decreased in CC. The present study aimed to investigate the role of miR-99a-5p in glycolysis in CC. For this purpose, the association between miR-99a and the prognosis of patients with CC from The Cancer Genome Atlas database was analyzed using Kaplan-Meier analysis. miR-99a-5p expression and Ras-related GTP binding D (RRAGD) expression were assessed using reverse transcription-quantitative PCR and western blot analysis. Cell proliferation and apoptosis were examined using an MTT assay and flow cytometry, respectively. Glucose uptake, lactate concentration and extracellular acidification rate were measured using a glucose uptake colorimetric assay, a lactate colorimetric assay and a Seahorse XFe96 extracellular flux analyzer, respectively. The association between miR-99a-5p and RRAGD was predicted using TargetScan 7.1, and was confirmed using dual luciferase reporter assay. The results revealed that miR-99a-5p expression was decreased and that of RRAGD was increased in CC tissues and cell lines. RRAGD was negatively regulated by miR-99a-5p. The overexpression of miR-99a-5p induced apoptosis and inhibited glycolysis in CC cells by targeting RRAGD. On the whole, the present study revealed a novel mechanism through which miR-99a-5p regulates cell apoptosis and glycolysis in CC, thus providing a potential therapeutic target for CC.
CircMCTP2 enhances the progression of bladder cancer by regulating the miR-99a-5p/FZD8 axis.
Liu Y, Zhang K, Yang X J Egypt Natl Canc Inst. 2024; 36(1):8.
PMID: 38494582 DOI: 10.1186/s43046-024-00206-6.
Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles.
Mondal D, Shinde S, Paul S, Thakur S, Velu G, Tiwari A Front Oncol. 2023; 13:1230273.
PMID: 37637043 PMC: 10448964. DOI: 10.3389/fonc.2023.1230273.
Xu Y, Sun Y, Song X, Ren J Front Cell Dev Biol. 2023; 11:1170059.
PMID: 37215076 PMC: 10192553. DOI: 10.3389/fcell.2023.1170059.
Jing W, Zhang R, Chen X, Zhang X, Qiu J J Pers Med. 2023; 13(3).
PMID: 36983711 PMC: 10054345. DOI: 10.3390/jpm13030529.
Zhai S, Li X, Lin T Comb Chem High Throughput Screen. 2023; 27(2):214-226.
PMID: 36927435 DOI: 10.2174/1386207326666230316103604.